Advertisement

ATRC

AtriCure, Inc.

Healthcare · USD

Set alert

Price alert · ATRC

All alert types
61.25 USD -1.23 -1.97%
As of Oct 30, 2026 Extended hours 61.25 0.00%
Bid
61.18 × 2
Ask
61.25 × 2
59.70 Day range 62.41
25.86 52-week range 62.48
YTD
+54.83%
1 year
+79.67%
Open
62.41
Prev close
62.48
Mkt cap
3.12B
Vol
967.36K
Avg vol
1.02M
EPS
0.21
P/E
291.67
Div yield
0.00%
More statistics
Low
59.70
High
62.41
Forward P/E
141.14
Beta
1.25
Short ratio
3.46
Inst. own
105.61%
Dividend
0.00
Ex-div date
Earnings
Nov 3, 2026
50-d avg
55.31
200-d avg
37.97
1y target
57.56

5D chart

Chart tools
Interval
ATRC five-day price chart58.959.960.962.063.0Oct 26Oct 27Oct 28Oct 29Oct 30

Key statistics

Market cap
3.12B
Enterprise value
3.08B
Trailing P/E
291.67
Forward P/E
141.14
PEG ratio
10.00
Price / sales
5.47
Price / book
6.03
EPS (TTM)
0.21
Beta
1.25
Dividend yield
0.00%
Payout ratio
0.00%
Profit margin
1.85%
Revenue (TTM)
569.62M
Revenue growth
12.80%
Free cash flow
48.81M
Total cash
167.79M
Total debt
74.22M
Return on equity
2.15%
Shares outstanding
50.87M
Short % of float
10.00%
50-day average
55.31
200-day average
37.97

Analyst view

Consensus: buy

Buy
Price target (mean) 57.56 -6.0% downside
Target (low)
36.00
Target (mean)
57.56
Target (high)
68.00
Ratings (0m) 10 7 buy · 3 hold · 0 sell
  • Strong buy3
  • Buy4
  • Hold3
  • Sell0
  • Strong sell0

Next earnings

Nov 3, 2026

Expected Nov 3, 2026. Consensus EPS estimate 0.01192.

Earnings history

Financials — quick view

All financials
ATRC Revenue — quarterly 153.60M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
ATRC Net income — quarterly 8.96M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
ATRC EPS — quarterly 0.18
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026

Earnings

ATRC recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 3, 2026Sep 30, 2026-0.04849———
Jul 23, 2026Jun 30, 2026-0.001670.18+0.18+10,878.44%
May 5, 2026Mar 31, 2026-0.070.0022+0.07+103.14%
Feb 17, 2026Dec 31, 2025-0.040030.06+0.10+249.89%
Oct 29, 2025Sep 30, 2025-0.11-0.01+0.10+90.91%
Jul 29, 2025Jun 30, 2025-0.15-0.13+0.02+13.33%

Upgrades / downgrades

ATRC analyst upgrades and downgrades
DateFirmActionFromTo
Oct 21, 2026CitizensmainMarket OutperformMarket Outperform
Oct 12, 2026BTIGmainBuyBuy
Oct 2, 2026Freedom Capital MarketsdownBuyHold
Sep 2, 2026NeedhammainBuyBuy
Aug 27, 2026Piper SandlermainOverweightOverweight
Aug 24, 2026BTIGmainBuyBuy

About AtriCure, Inc.

AtriCure, Inc. engages in the development, manufacture, and sale of devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, the Asia-Pacific, and internationally. It offers Isolator Synergy Ablation System clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, a single-use disposable RF products for the treatment of cardiac arrhythmias; cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; and EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation. It also provides cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; cryoXT probes, a cryoablation device designed specifically for Cryo Nerve Block therapy; LARIAT System, a solution for soft-tissue closure; Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; and Subtle Cannula's to support access for EPi-Sense catheters. In addition, the company sells various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.

Sector
Healthcare
Industry
Medical Instruments & Supplies
Country
United States
Website
atricure.com

News

Your note

Sign in to keep a note on ATRC — it syncs with the Stock Master app.

Insider holders

ATRC insider holders
InsiderRelationLatest transactionDateShares held
CARREL MICHAEL HChief Executive OfficerStock GiftJul 29, 2026792,694
DAHLQUIST KARL SOfficerSaleAug 23, 202687,319
DORAISWAMY VINAYAKOfficerSaleJul 27, 202686,511
JOHNSON B KRISTINEDirectorStock Award(Grant)May 17, 202655,954
NOZNESKY JUSTIN JOfficerSaleJul 28, 2026100,219
PRIVITERA SALVATOREChief Technology OfficerSaleSep 22, 2026142,745

Institution ownership

ATRC institution ownership
Holder% heldSharesValueReported
Blackrock Inc.8.80%4,474,548274.07MJun 29, 2026
Wellington Management Group, LLP6.87%3,495,603214.11MJun 29, 2026
Vanguard Portfolio Management LLC6.15%3,127,195191.54MJun 29, 2026
Hood River Capital Management LLC5.71%2,905,299177.95MJun 29, 2026
Alliancebernstein L.P.5.44%2,768,365169.56MJun 29, 2026
Vanguard Capital Management LLC4.31%2,190,413134.16MJun 29, 2026

Fund ownership

ATRC fund ownership
Holder% heldSharesValueReported
iShares Trust-iShares Core S&P Small-Cap ETF5.95%3,028,653185.50MSep 29, 2026
Manager Directed Portfolios-Hood River Small-Cap Growth Fund3.00%1,527,07393.53MJul 30, 2026
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund2.99%1,519,31293.06MJun 29, 2026
iShares Trust-iShares Russell 2000 ETF2.54%1,291,35879.10MSep 29, 2026
Delaware Group Equity Funds V-Nomura Small Cap Core Fund2.40%1,219,52674.70MMay 30, 2026
VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund2.17%1,102,11367.50MJun 29, 2026
Advertisement